Entropy Technologies LP Invests $860,000 in Pfizer Inc. (NYSE:PFE)

Entropy Technologies LP acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,711 shares of the biopharmaceutical company's stock, valued at approximately $860,000.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 3.2% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company's stock valued at $2,008,798,000 after purchasing an additional 2,241,609 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Pfizer by 2.8% during the 3rd quarter. Van ECK Associates Corp now owns 16,560,256 shares of the biopharmaceutical company's stock valued at $477,929,000 after buying an additional 456,168 shares during the last quarter. Diamond Hill Capital Management Inc. raised its holdings in Pfizer by 4.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 16,553,997 shares of the biopharmaceutical company's stock valued at $479,073,000 after acquiring an additional 658,420 shares in the last quarter. Federated Hermes Inc. grew its holdings in Pfizer by 3.3% during the 2nd quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company's stock worth $417,561,000 after acquiring an additional 470,003 shares in the last quarter. Finally, National Pension Service grew its stake in Pfizer by 18.1% in the third quarter. National Pension Service now owns 11,516,769 shares of the biopharmaceutical company's stock worth $333,295,000 after purchasing an additional 1,762,520 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target for the company. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a "market perform" rating and a $32.00 price objective on the stock. Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $33.58.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.17 on Thursday, hitting $26.55. The company's stock had a trading volume of 13,759,264 shares, compared to its average volume of 37,668,590. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The stock's 50-day moving average is $28.76 and its two-hundred day moving average is $28.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $150.46 billion, a price-to-earnings ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.33%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.